Status:
COMPLETED
Atazanavir Twice Daily
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
HIV Infections
Protease Inhibitor
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir administered twice-daily relative to historical data from atazanavir/ritonavir 300/100 mg, given once daily.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy male and female subjects between the ages of 18 to 45 years old with a BMI of 18 to 30 kg/m2
Exclusion
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00357721
Start Date
June 1 2006
End Date
September 1 2006
Last Update
April 6 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Hamilton, New Jersey, United States